Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton’s tyrosine kinase, in Phase I clinical trials in healthy volunteers. Science ShareTwitterFacebookXingLinkedin You May Also Like Science 30. Januar 2023 Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects. Science 30. Januar 2023 Midazolam microdosing applied in early clinical development for drug-drug interaction assessment. Science 30. Januar 2023 The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.